What It Is
SS-31 is a small, synthetic mitochondria-targeted tetrapeptide (four amino acids) that is better known by its clinical development name, elamipretide, along with earlier designations MTP-131 and Bendavia.[1] It belongs to the Szeto-Schiller family of aromatic-cationic peptides, originally designed to concentrate specifically within mitochondria rather than act at a cell-surface receptor.
Unlike many of the compounds covered on this site, elamipretide is a genuine investigational drug that has progressed into human clinical trials, including Phase 2 and Phase 3 studies, for specific rare mitochondrial diseases. That places it well ahead of unapproved research chemicals in terms of regulatory scrutiny, even though it is not yet a broadly FDA-approved medicine.
How It Works
SS-31 is proposed to interact with cardiolipin, a specialized lipid concentrated in the inner mitochondrial membrane that helps organize the electron transport chain and ATP synthase.[2] By stabilizing cardiolipin's interactions with respiratory-chain proteins, the peptide is thought to support more efficient electron transfer, reduce electron leak, and limit the reactive oxygen species that drive oxidative damage.
This mitochondrial, intracellular mechanism is distinctive: rather than binding a hormone receptor or extracellular target, SS-31 is designed to act deep inside the cell's energy-producing machinery. That mechanism aligns directly with diseases like Barth syndrome, which involves inherited defects in cardiolipin remodeling, but improved mitochondrial biomarkers in a dish or animal model still require direct human testing before clinical benefit can be assumed.[3]
What the Research Shows
Preclinical evidence is broad: mouse and cellular studies report improved mitochondrial respiration, reduced oxidative damage, and better skeletal-muscle bioenergetics in aged or injured tissue models.[4] Human evidence exists but is indication-specific and mixed. Clinical trials have evaluated elamipretide in primary mitochondrial myopathy (measuring walking distance and fatigue), Barth syndrome, heart failure, and ischemia-reperfusion settings, with results that vary by trial and endpoint rather than uniformly confirming benefit.[5]
The key distinction researchers draw is between biomarker improvement — such as better mitochondrial respiration readings — and clinical outcomes that matter to patients, like function, symptoms, or survival. For SS-31, the biomarker story is more consistent than the clinical-outcome story, and both should be read as disease-specific rather than generalizable to healthy adults seeking energy or anti-aging effects.
Safety & Side Effects
Because elamipretide has gone through registered clinical trials, there is real human safety data, though it varies by study, dose, route, and patient population. Commonly monitored findings include injection-site or administration-site reactions (many trials use subcutaneous dosing), gastrointestinal symptoms, headache, and fatigue.[5]
Trial safety data comes from closely monitored patients in rare-disease populations and does not automatically generalize to healthy people or to unapproved "SS-31" products sold online, which are not manufactured, tested, or dosed under the same controls as clinical-trial material. Long-term safety in broader populations remains an open question even where trial data exists.
Regulatory Status
Elamipretide (SS-31) is an investigational drug that has advanced through Phase 2 and Phase 3 clinical trials for conditions including Barth syndrome and primary mitochondrial myopathy, but it is not yet a broadly FDA-approved medicine in the United States.[6] Its approval and designation status is indication-specific and can change, so current FDA and DailyMed listings should be checked directly rather than assumed from past trial activity.
This mid-pipeline status — real human trials, but no general approval — sets SS-31 apart both from fully approved drugs and from unapproved research chemicals with no clinical development history. "SS-31 peptide" sold outside a regulated trial or approved product is not verified to match the formulation, purity, or dosing used in published clinical research.